World Pharma News Digest - 07.04.2014

[Ruslan David]

Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
Novartis announced today that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More's Power of One campaign. Zambia is the first beneficiary country of this campaign sponsored by Novartis.
Read more...
http://www.worldpharmanews.com/novartis/2747-novartis-and-malaria-no-more-provide-two-million-antimalarial-treatments-to-children-in-zambia

Zombie cancer cells eat themselves to live
A University of Colorado Cancer Center study recently published in the journal Cell Reports and presented at the American Association for Cancer Research (AACR) Annual Conference 2014 shows that the cellular process of autophagy in which cells "eat" parts of themselves in times of stress may allow cancer cells to recover and divide rather than die when faced with chemotherapies.
Read more...
http://www.worldpharmanews.com/research/2746-zombie-cancer-cells-eat-themselves-to-live

Clinical trial results inconsistently reported among journals, government website
Medical researchers often presented the findings of their clinical trials in a different way on a federal government website than they did in the medical journals where their studies were ultimately published, according to an Oregon Health & Science University analysis published April 1 in the Annals of Internal Medicine.
Read more...
http://www.worldpharmanews.com/research/2745-clinical-trial-results-inconsistently-reported-among-journals-government-website

Merck Serono enters into research agreement with Pfizer and Broad Institute
Merck Serono, the biopharmaceutical division of Merck, announced that its U.S. affiliate EMD Serono has signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients. The research project will be jointly funded by Merck Serono and Pfizer.
Read more...
http://www.worldpharmanews.com/merckkgaa/2744-merck-serono-enters-into-research-agreement-with-pfizer-and-broad-institute

Using light-heated water to deliver drugs
Researchers from the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, in collaboration with materials scientists, engineers and neurobiologists, have discovered a new mechanism for using light to activate drug-delivering nanoparticles and other targeted therapeutic substances inside the body.
Read more...
http://www.worldpharmanews.com/research/2743-using-light-heated-water-to-deliver-drugs

Bayer HealthCare to significantly increase production capacity in China
Bayer HealthCare will invest around EUR 100 million to significantly increase the production capacity of its plant in Beijing, China, in preparation for further demand of its products in the country. A respective agreement was signed in Germany on the occasion of the visit of the President of the People's Republic of China, Xi Jinping, by the CEO of Bayer AG, Dr Marijn Dekkers.
Read more...
http://www.worldpharmanews.com/bayer/2742-bayer-healthcare-to-significantly-increase-production-capacity-in-china

US, European cholesterol guidelines differ in statin use recommendations
Application of U.S. and European cholesterol guidelines to a European population found that proportions of individuals eligible for statins differed substantially, with one U.S. guideline recommending statins for nearly all men and two-thirds of women, proportions exceeding those of the other guidelines, according to a JAMA study released online to coincide with the 2014 American College of Cardiology Scientific Sessions.
Read more...
http://www.worldpharmanews.com/research/2741-us-european-cholesterol-guidelines-differ-in-statin-use-recommendations

PharmaNews.eu / Latest News

Choices in TB vaccine development
http://www.pharmanews.eu/research-and-development/1430-choices-in-tb-vaccine-development

Nanoparticles cause cancer cells to self-destruct
http://www.pharmanews.eu/research-and-development/1429-nanoparticles-cause-cancer-cells-to-self-destruct

UCB CEO, Roch Doliveux, to chair Innovative Medicines Initiative board for a second term
http://www.pharmanews.eu/research-and-development/1428-ucb-ceo-roch-doliveux-to-chair-innovative-medicines-initiative-board-for-a-second-term

Delegates from more than 30 countries to share the benefits of eHealth at WoHIT 2014
http://www.pharmanews.eu/conferences-and-events/1427-delegates-from-more-than-30-countries-to-share-the-benefits-of-ehealth-at-wohit-2014

AstraZeneca and MRC enter strategic collaboration
http://www.pharmanews.eu/astrazeneca/1426-astrazeneca-and-mrc-enter-strategic-collaboration

Where do you start when developing a new medicine?
http://www.pharmanews.eu/gsk/1425-where-do-you-start-when-developing-a-new-medicine

New online tool helps patient advocates navigate medicines development and evaluation process
http://www.pharmanews.eu/lilly/1424-new-online-tool-helps-patient-advocates-navigate-medicines-development-and-evaluation-process

With best regards,
Ruslan David
Administrator/Editor

DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany

eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu

PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us